MarketPeel
Insider Trading Intelligence
Pricing
…
JK

Justin B. Klee

AMLX
CO-CHIEF EXECUTIVE OFFICER · AMYLYX PHARMACEUTICALS, INC. · CIK 0001898314
FILING MIX · LIFETIME48%/52%
BUYS
20
SELLS
22
TOTAL VALUE
$8.64M
COMPANIES
1
ACTIVE SINCE
Jan 2022
HOLDINGS NOW
373,295
AVG SELL PX
$16.79
TRADE KIND
SHOWING 42 / 42
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
17 backtested trades · 8 horizons · 24 pending
Forward-return performance of every backtestable P/S trade by Justin B. Klee, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d17+70.59%-4.03%-0.62%-3.41%-1.33%—
14d17+41.18%-1.19%+0.14%-1.33%-0.12%—
30d17+41.18%+2.43%+0.65%+1.78%+0.71%—
60d17+29.41%+7.54%+0.02%+7.53%+7.60%—
90d17+41.18%+6.16%+2.49%+4.44%+6.12%—
180d17(5 pending)+41.67%+38.69%+7.90%+30.78%-0.97%—
1y17(7 pending)+30.00%+112.55%+20.56%+91.98%+48.42%—
2y17(12 pending)+60.00%-76.28%+48.83%-125.11%-134.79%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AMLX · 373,295 shares · as of Mar 5, 2026
0895,8701,791,7412,687,6113,583,4812023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 20 buys / 22 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
248,865——3,583,481Mar 5, 2026Mar 9, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
373,295——373,295Mar 5, 2026Mar 9, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
29,282$14.47$423.8K3,334,616Mar 2, 2026Mar 4, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
15,500$14.69$227.6K3,363,898Feb 2, 2026Feb 4, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
2,847——0Jan 16, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
2,847$7.57$21.6K3,381,393Jan 16, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
1,995$13.89$27.7K3,379,398Jan 16, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
136,193$13.58$1.85M3,378,546Jan 15, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
197,153$7.57$1.49M3,514,739Jan 15, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
197,153——2,847Jan 15, 2026Jan 20, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
7,715$11.09$85.6K3,317,586Jan 6, 2026Jan 8, 2026 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
29,775$14.37$428.0K3,325,501Sep 30, 2025Oct 2, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
200$15.01$3.0K3,325,301Sep 30, 2025Oct 2, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
21,490$3.46$74.5K3,355,276Mar 31, 2025Apr 2, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
270,177——270,177Mar 6, 2025Mar 10, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
180,118——3,376,766Mar 6, 2025Mar 10, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
4,595$3.15$14.5K3,196,648Mar 3, 2025Mar 5, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
36,310$1.57$57.0K3,201,243Feb 5, 2025Feb 6, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
36,310——0Feb 5, 2025Feb 6, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
11,855$3.47$41.1K3,164,933Feb 3, 2025Feb 5, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
7,471$4.04$30.2K3,176,788Jan 6, 2025Jan 8, 2025 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
63,690——36,310Nov 4, 2024Nov 6, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
63,690$1.57$100.0K3,184,259Nov 4, 2024Nov 6, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
18,589$3.20$59.4K3,120,569Sep 30, 2024Oct 2, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
380,000——380,000Apr 16, 2024Apr 18, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
179,850——3,139,158Apr 16, 2024Apr 18, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
4,135$18.73$77.4K2,959,308Mar 5, 2024Mar 7, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
190,000——190,000Feb 26, 2024Feb 28, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
126,667——2,963,443Feb 26, 2024Feb 28, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
5,841$16.33$95.4K2,836,776Jan 9, 2024Jan 11, 2024 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
225,000——225,000Mar 16, 2023Mar 20, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
50,000——2,842,617Mar 16, 2023Mar 20, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
96,555$31.84$3.07M2,796,062Mar 16, 2023Mar 20, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
3,445$32.48$111.9K2,792,617Mar 16, 2023Mar 20, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
1,846$36.79$67.9K2,892,617Jan 6, 2023Jan 10, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
4,122$36.08$148.7K2,894,463Jan 6, 2023Jan 10, 2023 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
334,520——0May 5, 2022May 6, 2022 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
334,520$0.37$123.8K2,898,585May 5, 2022May 6, 2022 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Co-Chief Executive Officer
4,870——0Jan 6, 2022Jan 10, 2022 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
337,500——337,500Jan 6, 2022Jan 10, 2022 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
75,000——2,564,065Jan 6, 2022Jan 10, 2022 ↗View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASE
Co-Chief Executive Officer
4,870——2,489,065Jan 6, 2022Jan 10, 2022 ↗View →
Other insiders · AMLX
Loading peer insiders…
About this filer
CIK 0001898314
ROLE
Co-Chief Executive Officer
PRIMARY
AMLX
COMPANIES
1
ACTIVE SINCE
Jan 2022
MARKETPEEL · /INSIDER/0001898314DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback